Enlicitide lowers LDL by 60% with little side effect
3 hours ago
- #Cholesterol
- #Cardiology
- #Drug Development
- A new experimental pill called enlicitide significantly reduces LDL cholesterol by up to 60% in high-risk patients already on statins.
- Enlicitide provides a pill-based alternative to injected PCSK9 inhibitors, potentially offering a more convenient option for millions.
- The study showed consistent cholesterol-lowering effects over a year with no significant safety issues compared to placebo.
- The pill must be taken on an empty stomach, and further research is ongoing to confirm its impact on heart attacks and strokes.
- Merck is seeking FDA approval for enlicitide under a fast-review program, with a larger trial involving 14,000 patients underway.